Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Perseid Achieves Astellas Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Perseid Achieves Astellas Milestone

Maxygen, Inc.’s majority-owned subsidiary, Perseid Therapeutics LLC, has achieved a preclinical milestone under its collaboration with Astellas Pharma, triggering a $5 million payment to Perseid.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Maxygen, Inc.’s majority-owned subsidiary, Perseid Therapeutics LLC, has achieved a preclinical milestone under its collaboration with Astellas Pharma, triggering a $5 million payment to Perseid. The goal of the collaboration is to co-develop and commercialize next-gen CTLA4-Ig therapeutics.

“This milestone represents important progress in our next-generation CTLA-4 program,” said Grant Yonehiro, chief executive officer of Perseid. “It exemplifies the outstanding work that has been accomplished by the Perseid-Astellas team. We are pleased to have such a strong collaboration with such an exceptional global partner.”


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters